TY - JOUR
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Analgesics, Opioid/adverse effects/therapeutic use
KW - Cancer Pain/drug therapy
KW - Case-Control Studies
KW - Dose-Response Relationship, Drug
KW - Female
KW - Humans
KW - Long QT Syndrome/chemically induced
KW - Male
KW - Methadone/therapeutic use
KW - Middle Aged
KW - Neoplasms/complications
KW - Opiate Substitution Treatment
KW - Palliative Care/methods
KW - Risk Factors
KW - QTc prolongation
KW - Methadone
KW - pain
KW - palliative care
AU - K. M. Juba
AU - T. M. Khadem
AU - D. J. Hutchinson
AU - J. E. Brown
A1 - 
AB - BACKGROUND: Methadone (ME) is commonly used in pain and palliative care (PPC) patients with refractory pain or intolerable opioid adverse effects (AEs). A unique ME AE is its corrected QT (QTc) interval prolongation risk, but most evidence exists in methadone maintenance therapy patients. OBJECTIVE: Our goal was to identify QTc interval prolongation risk factors in PPC patients receiving ME and other medications known to prolong the QTc interval and develop a risk stratification tool. DESIGN: We performed a case-control study of adult inpatients receiving ME for pain management. Settings/Subjects: Adult inpatients receiving ME with a QTc >470 msec (males) and >480 msec (females) were matched 1:2 according to age, history of QTc prolongation, and gender with ME patients who did not have a prolonged QTc interval. QTc prolongation risk factors were collected for both groups. Covariates were analyzed using conditional logistic regression. Classification and regression tree analysis was used to identify the ME dose associated with QTc prolongation. RESULTS: Predictors of QTc prolongation included congestive heart failure (CHF) (OR: 11.9; 95% CI: 3.7-38.2; p 45 mg per day (OR: 1.9; 95% CI: 0.8-4.8; p 45 mg per day (OR: 1.9; 95% CI: 0.8-4.8; p 45 mg per day.
AD - 1 Department of Pharmacy Practice, Wegmans School of Pharmacy, St. John Fisher College , Rochester, New York.; 2 Department of Pharmacy, University of Rochester Medical Center-Strong Memorial Hospital , Rochester, New York.; 1 Department of Pharmacy Practice, Wegmans School of Pharmacy, St. John Fisher College , Rochester, New York.; 1 Department of Pharmacy Practice, Wegmans School of Pharmacy, St. John Fisher College , Rochester, New York.
BT - Journal of palliative medicine
C5 - Opioids & Substance Use
CP - 7
CY - United States
DO - 10.1089/jpm.2016.0411
IS - 7
JF - Journal of palliative medicine
M1 - Journal Article
N2 - BACKGROUND: Methadone (ME) is commonly used in pain and palliative care (PPC) patients with refractory pain or intolerable opioid adverse effects (AEs). A unique ME AE is its corrected QT (QTc) interval prolongation risk, but most evidence exists in methadone maintenance therapy patients. OBJECTIVE: Our goal was to identify QTc interval prolongation risk factors in PPC patients receiving ME and other medications known to prolong the QTc interval and develop a risk stratification tool. DESIGN: We performed a case-control study of adult inpatients receiving ME for pain management. Settings/Subjects: Adult inpatients receiving ME with a QTc >470 msec (males) and >480 msec (females) were matched 1:2 according to age, history of QTc prolongation, and gender with ME patients who did not have a prolonged QTc interval. QTc prolongation risk factors were collected for both groups. Covariates were analyzed using conditional logistic regression. Classification and regression tree analysis was used to identify the ME dose associated with QTc prolongation. RESULTS: Predictors of QTc prolongation included congestive heart failure (CHF) (OR: 11.9; 95% CI: 3.7-38.2; p 45 mg per day (OR: 1.9; 95% CI: 0.8-4.8; p 45 mg per day (OR: 1.9; 95% CI: 0.8-4.8; p 45 mg per day.
PP - United States
PY - 2017
SN - 1557-7740; 1557-7740
SP - 722
EP - 728
EP - 
T1 - Methadone and Corrected QT Prolongation in Pain and Palliative Care Patients: A Case-Control Study
T2 - Journal of palliative medicine
TI - Methadone and Corrected QT Prolongation in Pain and Palliative Care Patients: A Case-Control Study
U1 - Opioids & Substance Use
U2 - 28186837
U3 - 10.1089/jpm.2016.0411
VL - 20
VO - 1557-7740; 1557-7740
Y1 - 2017
Y2 - Jul
ER -